Associated Papers
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.
Liu T et al.
Nature Communications, 2022
35347147 (PubMed )
Supplement: 41467_2022_29336_MOESM8_ESM.xlsx › Sheet1
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
Human erythroblasts with c-Kit activating mutations have reduced cell culture costs and remain capable of terminal maturation.
Couch T et al.
Experimental Hematology, 2019
Anaphylaxis as a clinical manifestation of clonal mast cell disorders.
Matito A et al.
Current Allergy and Asthma Reports, 2014
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.
Verstovsek S
European Journal of Haematology, 2013
Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.
Haenisch B et al.
Immunology, 2012
Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R et al.
The British Journal of Dermatology, 2008
Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A et al.
British Journal of Haematology, 2007
One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.
Sotlar K et al.
The American Journal of Pathology, 2003
Select a paper to view details